Oral therapy of recombinant Subtilisin QK-2 potentiates thrombolytic effect in a carrageenan-induced thrombosis animal model

•rSubtilisin QK has been shown to be resistant against pancreatic enzyme mimics.•rSubtilisin QK can be transferred into the bloodstream and all organs via intestinal absorption.•D-dimer and FDP levels elevated following rSubtilisin QK oral administration.•rSubtilisin QK has thrombolytic effects by oral gavage in vivo.•t-PA expression was increased by rSubtilisin QK, while PAI-1 showed the opposite trend.